lifestyle.xbode.org

Author: NervGen Pharma Corp.

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

April 27, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

March 13, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

March 4, 2026
NervGen Pharma to Participate at Upcoming Investor Conferences

February 18, 2026
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

February 17, 2026
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

February 16, 2026